Bellecapital International Ltd. Has $761,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Bellecapital International Ltd. lifted its position in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 3.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,394 shares of the biopharmaceutical company’s stock after purchasing an additional 528 shares during the quarter. Bellecapital International Ltd.’s holdings in Pfizer were worth $761,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Sound Shore Management Inc CT boosted its position in shares of Pfizer by 46.0% during the third quarter. Sound Shore Management Inc CT now owns 1,761,806 shares of the biopharmaceutical company’s stock worth $77,097,000 after purchasing an additional 555,152 shares in the last quarter. Consolidated Planning Corp boosted its position in shares of Pfizer by 21.4% during the third quarter. Consolidated Planning Corp now owns 4,680 shares of the biopharmaceutical company’s stock worth $205,000 after purchasing an additional 826 shares in the last quarter. Chevy Chase Trust Holdings LLC lifted its position in Pfizer by 1.2% in the 3rd quarter. Chevy Chase Trust Holdings LLC now owns 3,520,002 shares of the biopharmaceutical company’s stock valued at $154,036,000 after acquiring an additional 40,933 shares in the last quarter. V Wealth Advisors LLC lifted its position in Pfizer by 6.7% in the 3rd quarter. V Wealth Advisors LLC now owns 36,877 shares of the biopharmaceutical company’s stock valued at $1,613,000 after acquiring an additional 2,308 shares in the last quarter. Finally, JGP Global Gestao de Recursos Ltda. lifted its position in Pfizer by 91.0% in the 3rd quarter. JGP Global Gestao de Recursos Ltda. now owns 9,288 shares of the biopharmaceutical company’s stock valued at $406,000 after acquiring an additional 4,426 shares in the last quarter. 67.62% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on PFE shares. StockNews.com started coverage on shares of Pfizer in a research report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Bank of America cut shares of Pfizer from a “buy” rating to a “neutral” rating and set a $60.00 price objective on the stock. in a research report on Wednesday, January 4th. Wells Fargo & Company cut shares of Pfizer from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $54.00 to $50.00 in a research report on Tuesday, January 17th. Morgan Stanley boosted their price target on shares of Pfizer from $51.00 to $53.00 and gave the stock an “equal weight” rating in a research report on Wednesday, December 14th. Finally, UBS Group set a $55.00 price target on shares of Pfizer in a research report on Wednesday, January 18th. Seven investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $53.00.

Pfizer Stock Performance

Shares of Pfizer stock traded down $0.04 during trading on Wednesday, hitting $44.67. 1,500,541 shares of the stock were exchanged, compared to its average volume of 22,940,553. The stock has a market capitalization of $250.75 billion, a price-to-earnings ratio of 8.60, a price-to-earnings-growth ratio of 1.11 and a beta of 0.67. The company has a fifty day moving average price of $49.68 and a 200-day moving average price of $48.06. Pfizer Inc. has a 1-year low of $41.44 and a 1-year high of $56.32. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 0.35.

Pfizer (NYSE:PFEGet Rating) last released its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.31. The company had revenue of $22.64 billion for the quarter, compared to analyst estimates of $21.04 billion. Pfizer had a net margin of 29.81% and a return on equity of 43.95%. As a group, equities analysts predict that Pfizer Inc. will post 6.47 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 3rd. Stockholders of record on Friday, January 27th will be paid a dividend of $0.41 per share. The ex-dividend date is Thursday, January 26th. This is a positive change from Pfizer’s previous quarterly dividend of $0.40. This represents a $1.64 annualized dividend and a dividend yield of 3.67%. Pfizer’s payout ratio is currently 30.77%.

Pfizer Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.